Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Hasan, Ahasanul ; Zerin, Farzana ; Menon, Sreelakshmi N , et al. J. Pharmacol. Sci.,2022,150(4):211-222. DOI: 10.1016/j.jphs.2022.09.004 PubMed ID: 36344043
More
Abstract: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is reported to produce beneficial cardiovascular effects including a reduction in arterial contractility, and blood pressure. However, whether canagliflozin could directly relax resistance mesenteric arteries, underlying molecular mechanism and its role in regulating systemic blood pressure remain unclear. Here, we investigated the mechanism of regulation of small mesenteric artery contractility and its relevance for blood pressure regulation. Our pressure myography data showed that canagliflozin application rapidly produces a concentration-dependent vasodilation in mesenteric arteries. Such vasodilation was inhibited by concurrent inhibition of smooth muscle cell voltage-gated Kt channels KV1.5 (by 1 mM DPO-1), KV2.1 (by 100 nM guangxitoxin), and KV7 (by 10 mM linopirdine) but not by the inhibition of small-, intermediate-, and large-conductance Ca2t-activated Kt channels (SKCa by 1 mM apamin, IKCa 10 mM TRAM-34, and BKCa by 10 mM paxilline, respectively), ATP-sensitive (KATP) channels (by 10 mM glibenclamide), or SERCA pump (by 0.1 mM thapsigargin). Inhibition of SGLTs (by 1 mM phlorizin or the inhibition of endothelial signaling did not alter canagliflozin-evoked vasodilation. Consistently, acute canagliflozin treatment (4 mg/kg body weight) lowered systemic blood pressure in vivo. Overall, our data suggests that canagliflozin stimulates KV1.5, KV2.1, and KV7 channels, leading to vasodilation and a reduction of systemic blood pressure.
Keywords: Canagliflozin ; Mesenteric arteries ; Voltage-gated Kt channels ; Vasorelaxation ; Blood pressure
Purchased from AmBeed: 842133-18-0
CAS No. : | 842133-18-0 | MDL No. : | MFCD18251436 |
Formula : | C24H25FO5S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | XTNGUQKDFGDXSJ-ZXGKGEBGSA-N |
M.W : | 444.52 | Pubchem ID : | 24812758 |
Synonyms : |
JNJ 28431754;TA-7284;JNJ-24831754
|
Chemical Name : | (2S,3R,4R,5S,6R)-2-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
Signal Word: | Danger | Class: | N/A |
Precautionary Statements: | P201-P202-P280-P281-P305+P351+P338-P308+P313-P310-P405-P501 | UN#: | N/A |
Hazard Statements: | H318-H361 | Packing Group: | N/A |
GHS Pictogram: |
![]() ![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.